Selected research
Industry Research
Gene Site-Directed Mutagenesis Services Industry Research Report 2026
Market perspective
The global Gene Site-Directed Mutagenesis Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Gene Site-Directed Mutagenesis Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Gene Site-Directed Mutagenesis Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Gene Site-Directed Mutagenesis Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Gene Site-Directed Mutagenesis Services include Azenta Life Sciences, GenScript, Thermo Fisher Scientific, Charles River Laboratories, Genewiz, Creative Biolabs, NovoPro Bioscience Inc., ACGT, Inc. and Epoch Life Science, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Gene Site-Directed Mutagenesis Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gene Site-Directed Mutagenesis Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gene Site-Directed Mutagenesis Services Market by Company
Azenta Life Sciences
GenScript
Thermo Fisher Scientific
Charles River Laboratories
Genewiz
Creative Biolabs
NovoPro Bioscience Inc.
ACGT, Inc.
Epoch Life Science
Eurofins Genomics
NZYtech
Synbio Technologies
Tsingke
GenCefe
Generay
Gene Site-Directed Mutagenesis Services Segment by Type
Synonymous Mutations
Missense Mutation
Nonsense Mutation
Gene Site-Directed Mutagenesis Services Segment by Application
Medical Industry
Biological Research
Others
Gene Site-Directed Mutagenesis Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Site-Directed Mutagenesis Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Site-Directed Mutagenesis Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Site-Directed Mutagenesis Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gene Site-Directed Mutagenesis Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Synonymous Mutations
- Missense Mutation
- Nonsense Mutation
Applications
- Medical Industry
- Biological Research
- Others
Companies covered
- Azenta Life Sciences
- GenScript
- Thermo Fisher Scientific
- Charles River Laboratories
- Genewiz
- Creative Biolabs
- NovoPro Bioscience Inc.
- ACGT, Inc.
- Epoch Life Science
- Eurofins Genomics
- NZYtech
- Synbio Technologies
- Tsingke
- GenCefe
- Generay
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gene Site-Directed Mutagenesis Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Synonymous Mutations
- 2.2.3 Missense Mutation
- 2.2.4 Nonsense Mutation
- 2.3 Gene Site-Directed Mutagenesis Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Medical Industry
- 2.3.3 Biological Research
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Gene Site-Directed Mutagenesis Services Breakdown Data by Type
- 3.1 Global Gene Site-Directed Mutagenesis Services Historic Market Size by Type (2021-2026)
- 3.2 Global Gene Site-Directed Mutagenesis Services Forecasted Market Size by Type (2027-2032)
4 Gene Site-Directed Mutagenesis Services Breakdown Data by Application
- 4.1 Global Gene Site-Directed Mutagenesis Services Historic Market Size by Application (2021-2026)
- 4.2 Global Gene Site-Directed Mutagenesis Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gene Site-Directed Mutagenesis Services Market Perspective (2021-2032)
- 5.2 Global Gene Site-Directed Mutagenesis Services Growth Trends by Region
- 5.2.1 Global Gene Site-Directed Mutagenesis Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gene Site-Directed Mutagenesis Services Historic Market Size by Region (2021-2026)
- 5.2.3 Gene Site-Directed Mutagenesis Services Forecasted Market Size by Region (2027-2032)
- 5.3 Gene Site-Directed Mutagenesis Services Market Dynamics
- 5.3.1 Gene Site-Directed Mutagenesis Services Industry Trends
- 5.3.2 Gene Site-Directed Mutagenesis Services Market Drivers
- 5.3.3 Gene Site-Directed Mutagenesis Services Market Challenges
- 5.3.4 Gene Site-Directed Mutagenesis Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gene Site-Directed Mutagenesis Services Players by Revenue
- 6.1.1 Global Top Gene Site-Directed Mutagenesis Services Players by Revenue (2021-2026)
- 6.1.2 Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Gene Site-Directed Mutagenesis Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gene Site-Directed Mutagenesis Services Head Office and Area Served
- 6.4 Global Gene Site-Directed Mutagenesis Services Players, Product Type & Application
- 6.5 Global Gene Site-Directed Mutagenesis Services Manufacturers Established Date
- 6.6 Global Gene Site-Directed Mutagenesis Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gene Site-Directed Mutagenesis Services Market Size (2021-2032)
- 7.2 North America Gene Site-Directed Mutagenesis Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gene Site-Directed Mutagenesis Services Market Size by Country (2021-2026)
- 7.4 North America Gene Site-Directed Mutagenesis Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gene Site-Directed Mutagenesis Services Market Size (2021-2032)
- 8.2 Europe Gene Site-Directed Mutagenesis Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gene Site-Directed Mutagenesis Services Market Size by Country (2021-2026)
- 8.4 Europe Gene Site-Directed Mutagenesis Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gene Site-Directed Mutagenesis Services Market Size (2021-2032)
- 9.2 Asia-Pacific Gene Site-Directed Mutagenesis Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gene Site-Directed Mutagenesis Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gene Site-Directed Mutagenesis Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gene Site-Directed Mutagenesis Services Market Size (2021-2032)
- 10.2 South America Gene Site-Directed Mutagenesis Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gene Site-Directed Mutagenesis Services Market Size by Country (2021-2026)
- 10.4 South America Gene Site-Directed Mutagenesis Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gene Site-Directed Mutagenesis Services Market Size (2021-2032)
- 11.2 Middle East & Africa Gene Site-Directed Mutagenesis Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gene Site-Directed Mutagenesis Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gene Site-Directed Mutagenesis Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Azenta Life Sciences
- 12.1.1 Azenta Life Sciences Company Information
- 12.1.2 Azenta Life Sciences Business Overview
- 12.1.3 Azenta Life Sciences Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.1.4 Azenta Life Sciences Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.1.5 Azenta Life Sciences Recent Developments
- 12.2 GenScript
- 12.2.1 GenScript Company Information
- 12.2.2 GenScript Business Overview
- 12.2.3 GenScript Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.2.4 GenScript Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.2.5 GenScript Recent Developments
- 12.3 Thermo Fisher Scientific
- 12.3.1 Thermo Fisher Scientific Company Information
- 12.3.2 Thermo Fisher Scientific Business Overview
- 12.3.3 Thermo Fisher Scientific Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.3.4 Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.3.5 Thermo Fisher Scientific Recent Developments
- 12.4 Charles River Laboratories
- 12.4.1 Charles River Laboratories Company Information
- 12.4.2 Charles River Laboratories Business Overview
- 12.4.3 Charles River Laboratories Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.4.4 Charles River Laboratories Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.4.5 Charles River Laboratories Recent Developments
- 12.5 Genewiz
- 12.5.1 Genewiz Company Information
- 12.5.2 Genewiz Business Overview
- 12.5.3 Genewiz Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.5.4 Genewiz Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.5.5 Genewiz Recent Developments
- 12.6 Creative Biolabs
- 12.6.1 Creative Biolabs Company Information
- 12.6.2 Creative Biolabs Business Overview
- 12.6.3 Creative Biolabs Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.6.4 Creative Biolabs Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.6.5 Creative Biolabs Recent Developments
- 12.7 NovoPro Bioscience Inc.
- 12.7.1 NovoPro Bioscience Inc. Company Information
- 12.7.2 NovoPro Bioscience Inc. Business Overview
- 12.7.3 NovoPro Bioscience Inc. Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.7.4 NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.7.5 NovoPro Bioscience Inc. Recent Developments
- 12.8 ACGT, Inc.
- 12.8.1 ACGT, Inc. Company Information
- 12.8.2 ACGT, Inc. Business Overview
- 12.8.3 ACGT, Inc. Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.8.4 ACGT, Inc. Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.8.5 ACGT, Inc. Recent Developments
- 12.9 Epoch Life Science
- 12.9.1 Epoch Life Science Company Information
- 12.9.2 Epoch Life Science Business Overview
- 12.9.3 Epoch Life Science Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.9.4 Epoch Life Science Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.9.5 Epoch Life Science Recent Developments
- 12.10 Eurofins Genomics
- 12.10.1 Eurofins Genomics Company Information
- 12.10.2 Eurofins Genomics Business Overview
- 12.10.3 Eurofins Genomics Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.10.4 Eurofins Genomics Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.10.5 Eurofins Genomics Recent Developments
- 12.11 NZYtech
- 12.11.1 NZYtech Company Information
- 12.11.2 NZYtech Business Overview
- 12.11.3 NZYtech Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.11.4 NZYtech Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.11.5 NZYtech Recent Developments
- 12.12 Synbio Technologies
- 12.12.1 Synbio Technologies Company Information
- 12.12.2 Synbio Technologies Business Overview
- 12.12.3 Synbio Technologies Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.12.4 Synbio Technologies Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.12.5 Synbio Technologies Recent Developments
- 12.13 Tsingke
- 12.13.1 Tsingke Company Information
- 12.13.2 Tsingke Business Overview
- 12.13.3 Tsingke Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.13.4 Tsingke Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.13.5 Tsingke Recent Developments
- 12.14 GenCefe
- 12.14.1 GenCefe Company Information
- 12.14.2 GenCefe Business Overview
- 12.14.3 GenCefe Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.14.4 GenCefe Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.14.5 GenCefe Recent Developments
- 12.15 Generay
- 12.15.1 Generay Company Information
- 12.15.2 Generay Business Overview
- 12.15.3 Generay Revenue in Gene Site-Directed Mutagenesis Services Business (2021-2026)
- 12.15.4 Generay Gene Site-Directed Mutagenesis Services Product Portfolio
- 12.15.5 Generay Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst